Vertex Pharmaceuticals Incorporated

vrtx.com

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

244

Active

32

Phase 3

85

Total enrollment

35,393

Pipeline matrix

Showing 31 of 31 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Suzetrigine13
CTX0016
IVA46
VX-121/TEZ/D-IVA6
Pregabalin3
Povetacicept3
ELX/TEZ/IVA23
VNZ/TEZ/D-IVA4
VX-1473
Tacrolimus2
Biological/Vaccine1
VX-8801
VX-6702
VX-9939
VX-4074
VX-2641
Inaxaplin1
VX-522 mRNA therapy1
Midazolam7
TEZ7
Itraconazole4
VX-1182
Tezacaftor2
VX-8282
Deutivacaftor1
VX-5811
D-IVA1
VX-2721
Efavirenz1
VX-4331
Bupropion1

Next readouts

  • 2026-04-21
  • 2026-07-11
  • 2026-07-16
  • 2026-09-17
  • 2026-10-30
  • 2026-11-19
  • 2026-12-30
  • 2027-01-25
  • 2027-01-30
  • 2027-02-02

Top conditions

  • Cystic Fibrosis113
  • Pain26
  • Hepatitis C18
  • Acute Pain10
  • Hemoglobinopathies6
  • Rheumatoid Arthritis6
  • Chronic Hepatitis C6
  • Sickle Cell Disease5

Frequently asked questions about Vertex Pharmaceuticals Incorporated

How many clinical trials does Vertex Pharmaceuticals Incorporated have on ClinicalTrials.gov?
Vertex Pharmaceuticals Incorporated is listed as the lead sponsor on 244 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
How many of Vertex Pharmaceuticals Incorporated's trials are in Phase 3?
85 of Vertex Pharmaceuticals Incorporated's trials are in Phase 3, spread across 31 active drug programs.
What therapeutic areas does Vertex Pharmaceuticals Incorporated focus on?
Vertex Pharmaceuticals Incorporated's most-studied conditions on ClinicalTrials.gov are Cystic Fibrosis, Pain, Hepatitis C, Acute Pain, Hemoglobinopathies.
When are Vertex Pharmaceuticals Incorporated's next clinical trial readouts?
Vertex Pharmaceuticals Incorporated has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)”, expected around 2026-04-21.